Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
How would you manage a patient with erosive seronegative rheumatoid arthritis with IgG and IgM deficiency?
Related Questions
Would you use TNF inhibitor therapy in a patient with seropositive RA who had optic neuritis as a child without relapse as an adult?
Would you stop methotrexate or leflunomide if MCV increases after starting the medication with no other parameters of anemia or leukopenia?
How can we approach tapering or discontinuing biologic DMARDs in patient in their 80s with well controlled rheumatoid arthritis?
Would you be hesitant to continue a TNF inhibitor in a patient with stable RA and a history of COPD, Cor Pulmonale, severe reduced RVEF, but LVEF 65%?
How would you manage a patient with RA with newly diagnosed T-LGLL who was previously treated with Enbrel and is now flaring off Enbrel while on low dose methotrexate?
How do you assess the potential role of obesity in driving inflammatory joint symptoms?
For ICI arthritis, how soon do you start DMARDs?
How do you approach the use of immunosuppressive therapy in patients with rheumatoid arthritis and underlying immunodeficiency, such as IgA deficiency?
How do you approach management of RA in patients who have developed anti-drug antibodies to infliximab, especially if use of methotrexate is contraindicated and patients have tried and failed several other biologics?
Can serological markers such as KL-6, MMP-7, and anti-CarP be used to monitor interstitial lung disease in patients with rheumatoid arthritis in clinical practice?
